- Home
- INSW vs HUMAW Comparison
INSW vs HUMAW Comparison
Compare INSW & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- HUMAW
- Stock Information
- Founded
- INSW 1999
- HUMAW 2004
- Country
- INSW United States
- HUMAW United States
- Employees
- INSW N/A
- HUMAW 220
- Industry
- INSW Semiconductors
- HUMAW Biotechnology: Pharmaceutical Preparations
- Sector
- INSW Technology
- HUMAW Health Care
- Exchange
- INSW Nasdaq
- HUMAW Nasdaq
- Market Cap
- INSW 1.7B
- HUMAW N/A
- IPO Year
- INSW N/A
- HUMAW N/A
- Fundamental
- Price
- INSW $38.54
- HUMAW N/A
- Analyst Decision
- INSW Buy
- HUMAW
- Analyst Count
- INSW 2
- HUMAW 0
- Target Price
- INSW $52.00
- HUMAW N/A
- AVG Volume (30 Days)
- INSW 713.3K
- HUMAW 14.2K
- Earning Date
- INSW 08-06-2025
- HUMAW 03-21-2025
- Dividend Yield
- INSW 10.17%
- HUMAW N/A
- EPS Growth
- INSW N/A
- HUMAW N/A
- EPS
- INSW 6.47
- HUMAW N/A
- Revenue
- INSW $860,606,000.00
- HUMAW N/A
- Revenue This Year
- INSW N/A
- HUMAW N/A
- Revenue Next Year
- INSW $2.05
- HUMAW N/A
- P/E Ratio
- INSW $6.08
- HUMAW N/A
- Revenue Growth
- INSW N/A
- HUMAW N/A
- 52 Week Low
- INSW $27.20
- HUMAW $1.18
- 52 Week High
- INSW $60.70
- HUMAW $1.34
- Technical
- Relative Strength Index (RSI)
- INSW 56.28
- HUMAW N/A
- Support Level
- INSW $36.03
- HUMAW N/A
- Resistance Level
- INSW $38.61
- HUMAW N/A
- Average True Range (ATR)
- INSW 1.45
- HUMAW 0.00
- MACD
- INSW -0.12
- HUMAW 0.00
- Stochastic Oscillator
- INSW 64.20
- HUMAW 0.00
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About HUMAW Humacyte Inc. Warrant
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.